Hydrogenology
Hydrogenology editorial study record

Adjuvant Molecular Hydrogen Therapy in SLE-associated Pulmonary Arterial Hypertension: A Case Report on Immunomodulatory Effects on Regulatory and Effector Lymphocytes.

Liu C, Lu JW, Wu CH, Ho YJ, Lui SW, Hsieh TY, Wang KY, Liu FC. · In Vivo. 2026;40:14220.

HumanOther formsPublished 2026
Study record, not medical adviceThis page reports one source and Hydrogenology’s source-text extraction. It does not establish that molecular hydrogen is effective, safe or appropriate for any person. Human, animal and laboratory evidence must not be treated as equivalent.
Source and classification

What kind of evidence is this?

Evidence stream

Human

Reported design

Case report

Research topic

Cardiovascular and circulatory health

Administration classification

Other forms

Study result signal

Indeterminate for molecular hydrogen.

Outcome type

Clinical course and immune biomarkers in a single patient.

Reported in the source

Methods at a glance

Population or model

One patient with systemic lupus erythematosus-associated pulmonary arterial hypertension receiving ongoing medical care.

Sample

1 patient.

Duration

Longitudinal follow-up reported in the case article.

Intervention

One oral hydrogen-generating capsule daily as an adjunct to existing therapy.

Hydrogen form

Hydrogen generated after ingestion of a capsule; not Brown's gas.

H₂ specification

The capsule contained 170 mg hydrogen-enriched coral calcium; the article states an estimated hydrogen-generating capacity rather than a measured systemic dose.

H₂ flow

Not applicable — oral capsule.

O₂ delivered with H₂

No oxygen was co-delivered.

Comparator

No control; clinical course before and after adjunctive use.

Reported, not endorsed

Outcomes and reported result

Outcomes measured

Clinical course and regulatory and effector lymphocyte measurements.

Reported result

The report describes clinical stability and changes in selected immune-cell measures after adjunctive capsule use.

Results-extraction completeness

The full case report, timeline, measurements and concomitant treatments were checked.

A reported association, difference or mechanism is not automatically a clinical benefit. Null findings, outcome type, study design and precision all matter.

Interpretation limits

Cautions and applicability

Design and reporting cautions

A single uncontrolled case with concomitant treatment cannot establish that hydrogen caused the observed course or biomarker changes.

Applies directly to

This individual case only.

Preliminary appraisal framework

JBI Case Report Checklist — preliminary

Preliminary risk-of-bias status

Serious concerns

Appraisal rationale

No comparator and substantial confounding from disease course and concurrent therapy.

Appraisal domains

Single selected case · Co-interventions were present · Follow-up described in the report · Several outcomes were clinician- or patient-reported · No prespecified analysis plan

No single-study GRADE certainty rating is assigned. Certainty is assessed by important outcome across a complete eligible evidence set, not by attaching a final grade to one source.

Provenance

Sources and record status

Identifiers

PMID: 41482388 · DOI: 10.21873/invivo.14220

Publisher access

Free full article in PubMed Central.

Extraction basis

PubMed record and PubMed Central full text; extraction checked 9 August 2026.

Record revision

2026-08-10